SCHEMBL447710

SCHEMBL447710

CN(NS(=O)(=O)CC(=O)NN(C)C(=S)C1CCC1)C(=S)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.51
HSP90AB1 P08238 1/20 0.51
KMT2A Q03164 4/20 0.35
MEN1 O00255 3/20 0.35
ATM Q13315 1/20 0.35
GAA P10253 2/20 0.34
HTT P42858 2/20 0.34
MTNR1A P48039 1/20 0.34
MTNR1B P49286 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
ALDH1A1 P00352 4/20 0.34
MAPT P10636 3/20 0.34
ALOX12 P18054 3/20 0.34
LMNA P02545 2/20 0.34
USP2 O75604 2/20 0.33
HPGD P15428 2/20 0.33
HSD17B10 Q99714 1/20 0.33
ACHE P22303 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL448191 0.96 HSP90AA1 (0.53) HSP90AA1HSP90AB1KMT2AMEN1GAA
SCHEMBL448046 0.91 HSP90AA1 (0.56) HSP90AA1HSP90AB1KMT2AMEN1GAA
SCHEMBL464655 0.86 HSP90AA1 (0.68) HSP90AA1HSP90AB1KMT2AMEN1GAA
SCHEMBL446415 0.85 KMT2A (0.32) KMT2A
SCHEMBL445761 0.83 HSP90AA1 (0.59) HSP90AA1HSP90AB1KMT2AGAAHTT
SCHEMBL13292863 0.81 HSP90AA1 (0.46) HSP90AA1HSP90AB1ALDH1A1MAPT
SCHEMBL446744 0.80 HSP90AA1 (0.51) HSP90AA1HSP90AB1KMT2AMEN1ATM
SCHEMBL446362 0.80 HSP90AA1 (0.63) HSP90AA1HSP90AB1KMT2AMEN1ALDH1A1
SCHEMBL445596 0.80 HSP90AA1 (0.59) HSP90AA1HSP90AB1KMT2AMEN1GAA
SCHEMBL447212 0.80 HSP90AA1 (0.56) HSP90AA1HSP90AB1KMT2AHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680100-B2 Sulfonylhydrazide compounds for treating proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2014-03-25 US disclosed
US-8680100-B2 Sulfonylhydrazide compounds for treating proliferative disorders SYNTA PHARMACEUTICALS CORP. (US) 2014-03-25 US disclosed
US-20120065206-A1 COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. (US) 2012-03-15 US disclosed
US-20120065206-A1 COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. (US) 2012-03-15 US disclosed
EP-2370402-A2 COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS Synta Pharmaceuticals Corp. (US) 2011-10-05 EP disclosed
WO-2010065512-A2 COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. (US) 2010-06-10 WO disclosed
WO-2010065512-A2 COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS SYNTA PHARMACEUTICALS CORP. (US) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065206-A1 COMPOUNDS FOR TREATING PROLIFERATIVE DISORDERS PKD1, PKD2, PCNA HSP90AA1 2300/4885HSP90AB1 1711/4885KMT2A 1925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.